Darnitsa Group products

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering. Rosuvastatin increases the number of hepatic low-density lipoprotein (LDL) receptors on the cell surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of very low-density lipoproteins (VLDL), thereby reducing the total number of VLDL and LDL particles.

Valsartan is an active specific angiotensin II receptor antagonist for oral use. It selectively influences AT1 subtype receptors responsible for the known effects of angiotensin II. Elevated plasma angiotensin II levels after AT1 receptor blockade by valsartan can stimulate the unblocked AT2 receptor that balances the effect of the AT1 receptor. Valsartan does not show any partial agonist activity against the AT1 receptor, but has much greater (approximately 20,000 times) affinity for the AT1 receptor than for the AT2 receptor.